US Physical Therapy (USPH) Q3 2026 earnings summary
Event summary combining transcript, slides, and related documents.
Q3 2026 earnings summary
5 Nov, 2026Executive summary
Q3 revenue rose 12.9% to $222.6M and adjusted EBITDA increased to $27.8M from $23.9M; adjusted net income was $12.0M versus $10.1M.
Net income attributable to shareholders was $11.0M versus $13.1M; reported EPS was a $1.04 loss versus earnings of $0.48, partly reflecting redeemable non-controlling-interest revaluation.
Two completed hospital affiliations contributed $25M of Q3 revenue from 72 clinics; growth also reflected higher PT visits and stronger IIP performance.
Higher costs and a reversal in contingent earn-out fair value from a gain in 2025 to a loss in 2026 offset some operating growth.
Financial highlights
Q3 revenue was $222.6M versus $197.1M; operating income was $25.1M versus $25.3M, and net income attributable to shareholders was $11.0M versus $13.1M.
Q3 adjusted EBITDA was $27.8M versus $23.9M; adjusted net income was $12.0M versus $10.1M, and adjusted EPS was $0.80 versus $0.66.
Nine-month revenue was $634.9M versus $578.3M; adjusted EBITDA was $75.0M versus $70.3M, adjusted net income $30.2M versus $29.7M, and adjusted EPS $2.01 versus $1.96.
Nine-month operating cash flow was $63.9M versus $50.1M in 2025.
Outlook and guidance
Reaffirmed FY 2026 adjusted EBITDA guidance of $102M-$106M.
Q4 is the first full quarter with both hospital affiliations and all 72 clinics; management expects affiliation revenue to grow with referrals and further clinic additions.
Growth priorities include Metro de novos, tuck-in opportunities, multi-clinic and home-care practices, satellite clinics, and IIP acquisitions; 2027 guidance is expected with year-end results.
Elevated self-insured medical costs may persist into Q4; expense-control measures are expected to benefit future periods.
Financial and human-resources system implementation costs are expected to continue into 2027; further affiliation announcements depend on deal closings.
Latest events from US Physical Therapy
- Exclusive NYU Langone partnership and robust acquisitions drive growth and margin expansion.USPH
17th Annual Midwest IDEAS Conference - Q2 2026 revenue up 8.5% year-over-year; net income fell, but EBITDA guidance reaffirmed.USPH
Q2 2026 - Strong organic and acquisition-driven growth, with Medicare rate tailwinds and expanding high-margin segments.USPH
The 15th Annual East Coast IDEAS Conference - Q1 2026 revenue up 7.9% to $198.3M; EBITDA guidance reaffirmed; net income declined.USPH
Q1 2026 - Proxy seeks approval for directors, executive pay, auditor, and highlights governance and ESG.USPH
Proxy filing - Record 2025 growth and new alliances position for higher 2026 EBITDA and continued expansion.USPH
Q4 2025 - Q3 2024 delivered record patient volumes, 12% revenue growth, and major portfolio optimization.USPH
Q3 2024 - Record patient volumes and revenue growth, but net income and margins pressured by labor costs.USPH
Q2 2024 - Record Q1 patient volume, 18.1% revenue, and 23% net income growth, fueled by acquisitions.USPH
Q1 2025